M
Markus Rentsch
Researcher at Ludwig Maximilian University of Munich
Publications - 146
Citations - 3605
Markus Rentsch is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 29, co-authored 139 publications receiving 3154 citations. Previous affiliations of Markus Rentsch include University of Regensburg & Klinikum der Universität München.
Papers
More filters
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Nonbone Marrow-Derived Circulating Progenitor Cells Contribute to Postnatal Neovascularization Following Tissue Ischemia
Alexandra Aicher,Markus Rentsch,Ken-ichiro Sasaki,Joachim W. Ellwart,Fred Fändrich,Reiner Siebert,John P. Cooke,Stefanie Dimmeler,Christopher Heeschen +8 more
TL;DR: It is found that nonbone marrow- derived c-kit+CD45– progenitors contribute to postnatal neovascularization to an extent that is similar to that of bone marrow-derived progenitor cells.
Journal ArticleDOI
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the transplantation center munich
C. Wimmer,Markus Rentsch,Alexander Crispin,W. D. Illner,Helmut Arbogast,Christian Graeb,K. W. Jauch,Markus Guba +7 more
TL;DR: Interestingly, the use of IL-2-receptor antagonists significantly reduced the tumor risk of transplant recipients and mammalian target of rapamycin (mTOR) inhibitor-based immunosuppressive protocols showed a clear tendency for lower malignancy rates.
Journal ArticleDOI
Blumgart anastomosis for pancreaticojejunostomy minimizes severe complications after pancreatic head resection
Axel Kleespies,Markus Rentsch,Hendrik Seeliger,Markus Albertsmeier,K. W. Jauch,Christiane J. Bruns +5 more
TL;DR: A new transpancreatic suture technique (Blumgart anastomosis, BA), which aims to avoid shear forces during knot‐tying, is evaluated, which is found to be effective in reducing leakage from the pancreaticojejunostomy.
Journal ArticleDOI
Effect of graft steatosis on liver function and organ survival after liver transplantation.
Martin K. Angele,Markus Rentsch,Wolfgang H. Hartl,Benedikt Wittmann,Christian Graeb,Karl-Walter Jauch,Florian Loehe +6 more
TL;DR: Steatotic livers can be transplanted safely with good results for long-term organ survival if other contraindications are absent and the degree of donor steatosis does not depend on the degree.